<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056208</url>
  </required_header>
  <id_info>
    <org_study_id>PKE Pistachio</org_study_id>
    <nct_id>NCT04056208</nct_id>
  </id_info>
  <brief_title>Pistachios Blood Sugar Control, Heart and Gut Health</brief_title>
  <official_title>The Effect of Pistachios on Risk Factors for Cardiometabolic Disease in Individuals With Pre-diabetes: a Randomized, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-period randomized crossover study will be conducted to evaluate the effect of nighttime
      pistachio consumption (i.e., after dinner and before sleep) on fasting blood sugar levels,
      longer-term blood sugar control, and risk factors for heart disease. This study will also
      investigate how pistachios affects gut health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two-period randomized crossover trial will be conducted. Participants will be randomized to
      receive each treatment for 12 weeks followed by a minimum 4-week wash-out period. During the
      pistachio treatment, participants will consume two ounces per day (57 g) of pistachios as an
      evening snack. During the control phase subjects will be given advice to consume 1-2
      exchanges of carbohydrate as an evening snack, which is consistent with usual care. Markers
      of glycemic control, cardiovascular risk factors and gut health will be assessed at the
      beginning and the end of each treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting plasma glucose concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>fasting blood glucose assessed by blood draw and expressed in mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>HbA1c assessed by blood draw and expressed in micro IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>fasting serum insulin levels assessed by blood draw and expressed in micro IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral systolic and diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure measured assessed using a SphymoCor Ecel (Atcor Medical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central systolic and diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure measured assessed using a SphymoCor Ecel (Atcor Medical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid-femoral pulse wave velocity</measure>
    <time_frame>12 weeks</time_frame>
    <description>A measure of arterial stiffness assessed using a SphymoCor Ecel (Atcor Medical). A higher percentage value is indicative of greater arterial stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index (%)</measure>
    <time_frame>12 weeks</time_frame>
    <description>A measure of arterial stiffness assessed using a SphymoCor Ecel (Atcor Medical). A higher percentage value is indicative of greater arterial stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed using fasting blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed using fasting blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed using fasting blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed using fasting blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed using fasting blood draw and standardized HOMA-IR calculation. Fasting plasma glucose multiplied by fasting plasma insulin divided by 405.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured 10 cm above the navel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed using calibrated scale in Clinical Research Center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diet quality: Healthy Eating Index 2015</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed using the Healthy Eating Index 2015</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the composition of the gut microbiome</measure>
    <time_frame>12 weeks</time_frame>
    <description>microbiome composition assessed using fecal collection kit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Evening Pistachio Consumption</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will consume two ounces per day (57 g) of pistachios as an evening snack (i.e., after dinner and before sleep).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advice to consume a snack that contains 1-2 exchanges (15-30 g of carbohydrate) as an evening snack - this is consistent with the current standard of care for people with impaired fasting glucose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pistachio</intervention_name>
    <description>Unsalted pistachios</description>
    <arm_group_label>Evening Pistachio Consumption</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Advice and resources will be provided</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥25 and ≤45 kg/m2

          -  Fasting plasma glucose 100 - 125 mg/dL

          -  non-Smoking

        Exclusion Criteria:

          -  Diagnosed diabetes or fasting glucose &gt;126 mg/dl

          -  Systolic blood pressure &gt;160mmHg or diastolic blood pressure &gt;100mmHg)

          -  Prescribed anti-hypertensive, lipid lowering or glucose lowering drugs

          -  Established cardiovascular disease, stroke, diabetes, liver, kidney or autoimmune
             disease or inflammatory conditions

          -  Use of supplements (psyllium, fish oil, soy lecithin, phytoestrogens) and botanicals
             and not willing to cease for the duration of the study

          -  Women who are pregnant, lactating, planning to become pregnant or have given birth in
             the past year

          -  Weight loss of &gt;=10% of body weight within the 6 months prior to enrolling in the
             study

          -  Smoking or use of any tobacco products

          -  Allergy/intolerance/sensitive to pistachios

          -  Consumption of &gt;14 alcoholic drinks/week

          -  Shift-workers and those who cannot consume a snack in the evening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristina S Petersen</last_name>
    <phone>8148638622</phone>
    <email>kup63@psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Arnold</last_name>
    <phone>814-863-8305</phone>
    <email>jqr9@psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pennsylvania State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina S Petersen, PhD</last_name>
      <phone>814-863-8622</phone>
      <email>kup63@psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Terry Riley</last_name>
      <phone>814 863 8056</phone>
      <email>tmr359@psu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

